Daily Oral Pamidronate in Women and Men With Osteoporosis: A 3-Year Randomized Placebo-Controlled Clinical Trial With a 2-Year Open Extension

Brumsen, Caroline; Papapoulos, Socrates E.; Lips, Paul; Geelhoed-Duijvestijn, Petronella; Hamdy, Neveen A. T.; Landman, J.O.; McCloskey, Eugène; Netelenbos, J. C.; Pauwels, E. K. J.; Roos, Jan C.; Valentijn, R. M.; Zwinderman, Aeilko H.

doi:10.1359/jbmr.2002.17.6.1057

Cited by 69 publications

(31 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Only limited evidence from small RCT is available [Brumsen et al 2002;Reid et al 1994]. Pamidronate may potentially be efficacious against vertebral fractures (however, this was only backed by evidence from one of the studies [Brumsen et al 2002] Bazedoxifene. Bazedoxifene is also only effective against vertebral fractures [Silverman et al 2008], i.e.…”

Section: Bisphosphonatesmentioning

confidence: 99%

New strategies for osteoporosis patients previously managed with strontium ranelate

Vestergaard

2014

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Abstract:The aim of this article is to describe potential alternatives to patients no longer eligible for management with strontium ranelate for osteoporosis according to the recommendations by the European Medicines Agency. A systematic search of Pubmed was done for papers on fracture efficacy of various treatments for osteoporosis, and potential harms especially in terms of cardiovascular events and stroke. The results showed that drugs more efficacious in terms of relative risk reduction of fractures than strontium ranelate were alendronate, risedronate, zoledronate, and denosumab. Raloxifene, as for strontium, may be associated with an increased risk of deep venous thromboembolism and fatal stroke. In terms of cardiovascular events special attention may be given to calcium supplements. Thus, patients at risk of stroke and ischemic cardiac events such as acute myocardial infarction should not use strontium ranelate. Ideally more efficacious drugs in terms of fracture reduction should be used such as alendronate, risedronate, zoledronate or denosumab. Raloxifene may pose a special problem as this too may be associated with an increased risk of fatal strokes. Other less-potent drugs in terms of fracture reduction should only be used if no alternatives are available (ibandronate, pamidronate, clodronate). Parathyroid hormone or analogs may be used for a limited time interval in specially selected patients and needs to be followed up with antiresorptive treatment to prevent loss of the bone gained. However, it should be remembered that no head-to-head comparison studies exist.

show abstract

Section: Bisphosphonatesmentioning

confidence: 99%

New strategies for osteoporosis patients previously managed with strontium ranelate

Vestergaard

2014

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

show abstract

“…These data add to and provide support for findings from the Austrian Breast and Colorectal Cancer Study Group trial 12 (ABCSG-12) bone substudy and the Zometa-Femara Adjuvant Synergy companion trials (Z-FAST, ZO-FAST, and E-ZO-FAST), which show that ZOL improves BMD in patients receiving adjuvant endocrine therapy for early BC. Bisphosphonates other than ZOL (ie, pamidronate, risedronate, and clodronate) also have been shown to prevent CTIBL [56][57][58][59][60], as has denosumab [16,61].…”

Section: Cancer Therapy and Bone Healthmentioning

confidence: 99%

Zoledronic Acid in the Treatment of Early-Stage Breast Cancer: Is There a Final Verdict?

Gnant

2011

Curr Oncol Rep

View full text Add to dashboard Cite

Breast cancer, which preferentially metastasizes to bone, is the most common malignancy among women worldwide and is a leading cause of death. Clinical data from large, phase 3 trials (ie, ABCSG-12, ZO-FAST, and AZURE) demonstrate significantly improved disease-free survival with zoledronic acid in some patient populations with early breast cancer. Although the interim results from the AZURE trial did not show a disease-free survival benefit with zoledronic acid in the overall patient population, subset analyses showed that zoledronic acid significantly improved disease-free survival in women with established postmenopausal status at baseline. Similarly, subset analyses of the ABCSG-12 trial showed greater benefits from zoledronic acid in patients over 40 years of age who theoretically would have achieved more complete ovarian suppression. Together, these data support a potential role for zoledronic acid beyond bone health in breast cancer and suggest that the endocrine environment may influence the anticancer potential of zoledronic acid.

show abstract

“…When given daily, they suppress bone resorption and turnover, increase bone mineral density (BMD), maintain or improve structural and material properties of bone and thereby reduce the risk of fractures. [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19] However, daily administration of nitrogen-containing bisphosphonates is inconvenient because of strict dosing instructions, and may also be associated with gastrointestinal adverse effects. These reduce adherence to treatment and can diminish the therapeutic potential of bisphosphonates.…”

mentioning

confidence: 99%

Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate

Papapoulos

Schimmer²

2008

Postgraduate Medical Journal

View full text Add to dashboard Cite

Bisphosphonates reduce the rate of bone resorption and bone remodelling. Given daily, they decrease the risk of fractures in postmenopausal osteoporosis. When bisphosphonates were given at extended drug-free intervals this antifracture efficacy was generally not seen. This may be due to the different pattern of bone remodelling changes. Data from randomised clinical studies of ibandronate, given orally or intravenously, at different doses and for variable time intervals to women with osteoporosis were examined to explore the relationship between intermittent bisphosphonate therapy, changes in bone resorption and fracture risk. The magnitude of the reduction of the rate of bone resorption at the end of the drug-free interval rather than its fluctuation pattern after bisphosphonate administration determines antifracture efficacy, provided that these fluctuations occur within the premenopausal range. Prolongation of the drug-free interval beyond 2 weeks should be compensated by a dose higher than the cumulative daily dose.

show abstract

Daily Oral Pamidronate in Women and Men With Osteoporosis: A 3-Year Randomized Placebo-Controlled Clinical Trial With a 2-Year Open Extension

Cited by 69 publications

References 46 publications

New strategies for osteoporosis patients previously managed with strontium ranelate

New strategies for osteoporosis patients previously managed with strontium ranelate

Zoledronic Acid in the Treatment of Early-Stage Breast Cancer: Is There a Final Verdict?

Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate

Contact Info

Product

Resources

About